Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Palovarotene Clear all
Completed No phase listed Observational

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

NCT02322255
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 3 Interventional Results available

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

NCT05027802
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
14 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 5, 2026, 11:52 PM EDT
Recruiting No phase listed Observational

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06089616
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
8 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 5, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional Results available

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02521792
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

NCT02190747
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene, Placebo
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 5, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of Palovarotene for the Treatment of MO

NCT03442985
View directory record Official record
Conditions
Exostoses, Multiple Hereditary
Interventions
Palovarotene 2.5 mg, Palovarotene 5.0 mg, Placebo
Drug · Other
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
2 Years to 14 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

NCT04829773
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene, midazolam
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

NCT06908954
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

NCT03312634
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
4 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

NCT02279095
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene dose level 1, Palovarotene dose level 2, Palovarotene dose level 3, Palovarotene dose level 4
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 5, 2026, 11:52 PM EDT